A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Running, not enrolling · Phase 3

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Key facts

Study ID

NCT05827016

Run by

Bristol-Myers Squibb

People needed

1230

Starts

2023-06-22

Expected to finish

2036-01-01

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of symptomatic multiple myeloma (MM).
• Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
• Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone [D-VTd] and daratumumab + bortezomib/ lenalidomide/dexamethasone [D-VRd]), or VCd / daratumumab + bortezomib/cyclophosphamide/dexamethasone [D-VCd], and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
• Participants within 12 months (single transplant) or 15 months (tandem transplant) from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria.

You may not qualify if…

• Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy.
• Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
• Known central nervous system/meningeal involvement of MM.
• Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Mayo Clinic Hospital - Florida — Jacksonville, Florida, United States
• Local Institution - 0308 — Tampa, Florida, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Cleveland Clinic — Weston, Florida, United States
• University Cancer & Blood Center — Athens, Georgia, United States
• The Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Augusta University - Georgia Cancer Center — Augusta, Georgia, United States
• Local Institution - 0237 — Chicago, Illinois, United States
• University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion — Westwood, Kansas, United States
• Maryland Oncology Hematology, PA- Clinton — Clinton, Maryland, United States
• UMass Memorial Medical Center — Worcester, Massachusetts, United States
• University of Michigan - Rogel Cancer Center — Ann Arbor, Michigan, United States
• Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit — Detroit, Michigan, United States
• Cancer & Hematology Centers of Western Michigan (CHCWM) — Grand Rapids, Michigan, United States
• Mayo Clinic Cancer Center (MCCC) - Rochester — Rochester, Minnesota, United States
• Hattiesburg Clinic - Hematology & Oncology — Hattiesburg, Mississippi, United States
• Morristown Medical Center — Morristown, New Jersey, United States
• Perlmutter Cancer Center - Sunset Park — Brooklyn, New York, United States
• Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola — Mineola, New York, United States
• NYU Langone Health — New York, New York, United States
• Columbia University Medical Center - Herbert Irving Pavilion Location — New York, New York, United States
• Optum Medical Care PC — Westbury, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Novant Health Cancer Institute - Elizabeth — Charlotte, North Carolina, United States
• Rocky Mountain Cancer Centers — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.